Actively Recruiting
A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)
Led by M.D. Anderson Cancer Center · Updated on 2026-02-02
25
Participants Needed
1
Research Sites
37 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical research study is to gather information about the quality of life benefits of cancer patients with intermediate risk PE who underwent thrombectomy. The safety of thrombectomy in this patient population will also be studied.
CONDITIONS
Official Title
A Prospective Single Center, Single Arm, Single-institution Registry That Aims to Assess the Safety and Quality of Life Benefits of Computer-assisted Vacuum Thrombectomy (CAVT) in the Treatment of Cancer Patients With Intermediate Risk Pulmonary Embolism (PE)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with current or prior diagnosis of cancer
- Confirmed pulmonary embolism by computed tomographic pulmonary angiography showing a filling defect in at least one main or proximal lobar pulmonary artery
- Intermediate risk pulmonary embolism as defined by institutional PERT algorithm
- Candidate for standard of care pulmonary thrombectomy
- Age 18 years or older
- ECOG performance status 0 to 3
- Adequate organ and marrow function including absolute neutrophil count ≥ 1,000/mcL and platelets ≥ 30,000/mcL
- No specific renal function requirements due to procedure
- For female patients: post-menopausal status or negative pregnancy test with specific criteria based on age and hormonal status
- All previous systemic therapies allowed including chemotherapy, immunotherapy, or targeted therapy
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Hemodynamic instability including cardiac arrest, obstructive shock, persistent hypotension, or need for vasopressor/inotropic support
- Patients on extracorporeal membrane oxygenation (ECMO)
- Diagnosis of chronic thromboembolic pulmonary hypertension or disease
- Imaging or clinical findings indicating catheter intervention is not appropriate, including large volume lung metastases or pulmonary infarct
- Allergy, hypersensitivity, or heparin induced thrombocytopenia
- Severe active infection requiring treatment at enrollment
- Absolute neutrophil count below 1000/mm3 within 6 weeks of screening
- Life expectancy less than 90 days
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
V
Varshana Gurusamy, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here